FDA Authorizes First Device to Continuously Monitor Glucose and Ketones

Why it matters locally: The authorization of the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System will offer new options for managing diabetes for the estimated 672,834 adults in Massachusetts living with the condition.

The U.S. Food and Drug Administration has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. This authorization marks the first time a wearable device has gained approval to continuously monitor both ketone levels and blood sugar. Individuals aged two years and older who live with diabetes can now use this system. The device provides continuous data on these two biomarkers.